Bosentan

Heart Disease

Volumn 5, Issue 2, 2003, Pages 161-169

  Cheng, Judy W M ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Bosentan; Endothelin antagonism; Heart failure; Pulmonary hypertension

Indexed keywords

ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; CYCLOSPORIN A; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLIBENCLAMIDE; KETOCONAZOLE; LOSARTAN; NIMODIPINE; PLACEBO; PROSTACYCLIN; SIMVASTATIN; VASODILATOR AGENT; WARFARIN;

ANEMIA; CARDIOPULMONARY HEMODYNAMICS; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONGENITAL MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; EXERCISE; EXERCISE TOLERANCE; FATIGUE; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART FAILURE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LEG EDEMA; LIVER DYSFUNCTION; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; NAUSEA; PHARMACEUTICS; PHARMACODYNAMICS; PREGNANCY; PRESCRIPTION; PROGNOSIS; PRURITUS; PULMONARY HYPERTENSION; REVIEW; RHINOPHARYNGITIS; STILLBIRTH; TERATOGENICITY; TREATMENT OUTCOME; VERTIGO; VOMITING; WORLD HEALTH ORGANIZATION;

ANTIHYPERTENSIVE AGENTS; DRUG LABELING; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIAL ISCHEMIA; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 0038374932     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.HDX.0000061696.83820.51     Document Type: Review

References (49)

1. Frishman WH, Kaur S, Singh I, Tamirisa P. Endothelin as a therapeutic target in the treatment of cardiovascular disease. In: Frishman WH, Sonnenblick EH, Sica D, eds. Cardiovascular Pharm-Acotherapeutics. 2nd ed. New York, NY: McGraw-Hill; 2003;527-543.
2. Levin E. Endothelins. N Engl J Med. 1995;333:356-63.
3. Parker JD, Thiessen JJ, Reilly R, et al. Human endothelin-1 clearance kinetics revealed by a radiotracer technique. J Pharmacology Experimental Therapeutics. 1999;289:261-265.
4. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332:411-415.
5. Ellahham SH, Charlon V, Abassi Z, et al. Bosentan and the endothelin system in congestive heart failure. Clin Cardiol. 2000;23:803-807.
6. Battistini B, Chailler P, D'Orleans-Juste P, et al. Growth regulatory properties of endothelins. Peptides. 1993;14(2):385-99.
7. Kaddoura S, Firth JD, Boheler KR, et al. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Circulation. 1996;93:2068-2079.
8. Muller DN, Mervaala EM, Schmidt F, et al. Effect of bosentan on NF-kb, inflammation, and tissue factor in angiotensin II-induced end organ damage. Hypertension. 2000;36:282-290.
9. Mansoor AM, Honda M, Saida K, et al. Endothelin induced collagen remodeling in experimental pulmonary hypertension. Biochem Biophys Res Commun. 1995;215(4):981-986.
10. Piacentini L, Honda M, Saida K, et al. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C. J Mol Cell Cardiol. 2000;32(4):565-576.
11. Peifley KA, Winkles JA. Angiotensin II and endothelin-1 increase fibroblast growth factor-2 m-RNA expression in vascular smooth muscle cells. Biochem Biophys Res Commun. 1998;242(1):202-208.
12. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2000;103:72-77.
13. Pacher R, Stanek B, Hulsmann M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol. 1996;27: 633-641.
14. Benigni A, Zoja C, Coma D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993;44:440-444.
15. Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353:133-138.
16. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
17. Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol. 1995;26(7):1581-1585.
18. Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. 2002;105:1034-1036.
19. Actelion Pharmaceuticals US, Inc. Tracleer™, Bosentan Tablets. South San Francisco, CA: Actelion Pharmaceuticals; 200.1.
20. Binet I, Wallnofer A, Weber C, et al. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporin A. Kidney Int. 2000;57:224-231.
21. Weber C, Gasser R, Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos. 1999;27:810-815.
22. Weber C, Schmitt R, Bimboeck H, et al. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol. 1999;39:703-714.
23. Weber C, Schmitt R, Bimboeck H, et al. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther. 1996;60:124-137.
24. Dingemanse J, Bodin F, Weidekamm E, et al. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J Clin Pharmacol. 2002;42:283-289.
25. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69:223-231.
26. Rashid A, Lehrman S, Romano P, et al. Primary pulmonary hypertension. Heart Disease. 2000;2:422-430.
27. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325(21): 1468-1475.
28. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998;338: 273-277.
29. Frishman WH, Azizad M, Agarwal Y, Kang DW. Use of prostacyclin and its analogues in the treatment of pulmonary hypertension and other cardiovascular diseases. In: Frishman WH, Sonnenblick EH, Sica D, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw-Hill; 2003;429-442.
30. Perez-Penate G, Julia-Serda G, Pulido-Duque JM, et al. One-year continuous inhaled nitric oxide for primary pulmonary hypertension. Chest. 2001;119:970-973.
31. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo controlled study. Lancet. 2001;358: 1119-1123.
32. Sorenson HM. Dyspnea assessment. Respir Care. 2000;45:1331-1338.
33. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
34. Williamson DJ, Wallman LL, Jones E, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation. 2000;102:411-418.
35. LeJemtel TH, Sonnenblick EH, Frishman WH. Diagnosis and management of heart failure. In: Fuster V, Alexander RW, O'Rourke RA, eds. Hurst's The Heart. 10th ed. New York, NY: McGraw-Hill; 2001:687-724.
36. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endotheline-1 mediated vasoconstriction in severe heart failure. Lancet. 1995;346:732-736.
37. Sutsch G, Bertel O, Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther. 1997;10:717-725.
38. Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98:2262-2268.
39. Packer M. Multicenter, double-blind, placebo-controlled study of long term endothelin blockade with bosentan in chronic heart failure - results of the REACH-1 trial [abstract]. Circulation. 1998;98(suppl 17):1-3.
40. Packer M. ENABLE - the role of bosentan in CHF. American College of Cardiology Meeting, Atlanta, GA, March 17-20, 2002. Available at: http://www.acc.org/2002ann_meeting/ssnews/enable.htm. Accessed on June 8, 2002.
41. Krum H, Viskoper RJ, Lacourciere Y, et al., for the Bosentan Hypertension Investigators. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338:784-790.
42. Miyauchi T, Yanagisawa M, Tomizawa T, et al. Increased plasma concentrations in endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989;1:53-54.
43. Wenzel RR, Fleisch M, Shaw S, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation. 1998;98:2235-2240.
44. Weber C, Banken L, Birnboeck H, e.t al. The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. Br J Clin Pharmacol. 1999;47:701-706.
45. van Giersbergen PL, Treiber A, Clozel M, et al. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther. 2002;71(4):253-262.
46. Weber C, Banken L, Birnboeck H, et al. Effect of the endothelinreceptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39:847-854.
47. Van Giersbergen PL, Halabi A, Dingemanse J. Single- and multipledose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol. 2002;53:589-595.
48. Dingemanse J, Schaarschmidt D, Van Giersbergen PL. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Br J Clin Pharmacol. 2002;53:547P.
49. Wight E, Kung CF, Moreau P, et al. Chronic blockade of nitric oxide-synthetase and endothelin receptors during pregnancy in the rat: effect on pregnancy outcome. J Soc Gynecol Investig. 1998;5:132-139.